CG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.06B

+11.88%

1.060

+15.17%

1.14B

+8.97%

1.165

+2.23%

1.19B

+20.61%

1.111

+22.07%

Estimates Revision

The market is revising Downward the revenue expectations for The Carlyle Group Inc. (CG) for FY2025, with the revenue forecasts being adjusted by -6.22% over the past three months. During the same period, the stock price has changed by 9.12%.

Revenue Estimates for FY2025

Revise Downward

-6.22%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.4%

In Past 3 Month

Stock Price

Go Up

+9.12%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast CG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CG is 66.70 USD with a low forecast of 51.00 USD and a high forecast of 77.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

4 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

51.00

Averages

66.70

High

77.00

Current: 0.000

Low

51.00

Averages

66.70

High

77.00

Morgan Stanley

Sean Laaman

Overweight

maintain

$82 -> $89

2026-01-08

New

Reason

Morgan Stanley

Sean Laaman

Price Target

$82 -> $89

2026-01-08

New

maintain

Overweight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on CG Oncology to $89 from $82 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Wolfe Research

Steven Chubak

Outperform

maintain

$70 -> $83

2026-01-07

New

Reason

Wolfe Research

Steven Chubak

Price Target

$70 -> $83

2026-01-07

New

maintain

Outperform

Reason

Wolfe Research analyst Steven Chubak raised the firm's price target on Carlyle to $83 from $70 and keeps an Outperform rating on the shares as part of the firm's Top 10 Themes for 2026 note on the Banks, Brokers, and Alternative Managers. Heading into 2026, the firm notes Retail Brokers and Alts are its favorite subsectors and names Carlyle as one of its top picks in the sector

BofA

Buy

maintain

$60 -> $62

2026-01-06

New

Reason

BofA

Price Target

$60 -> $62

2026-01-06

New

maintain

Buy

Reason

BofA raised the firm's price target on CG Oncology to $62 from $60 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Barclays

Equal Weight

downgrade

$68 -> $65

2025-12-15

Reason

Barclays

Price Target

$68 -> $65

2025-12-15

downgrade

Equal Weight

Reason

Barclays lowered the firm's price target on Carlyle to $65 from $68 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the brokers, asset managers and exchanges group as part of its 2026. Market conditions "look constructive" going into 2026, particularly for the alternative asset managers and wealth brokers, the analyst tells investors in a research note. Barclays sees a more mixed outlook for the exchanges and traditional asset managers.

Barclays

Benjamin Budish

Overweight

maintain

$65 -> $68

2025-12-12

Reason

Barclays

Benjamin Budish

Price Target

$65 -> $68

2025-12-12

maintain

Overweight

Reason

Barclays analyst Benjamin Budish raised the firm's price target on Carlyle to $68 from $65 and keeps an Overweight rating on the shares. The firm adjusted targets in the brokers, asset managers and exchanges group as part of its 2026. Market conditions "look constructive" going into 2026, particularly for the alternative asset managers and wealth brokers, the analyst tells investors in a research note. Barclays sees a more mixed outlook for the exchanges and traditional asset managers.

UBS

Michael Brown

initiated

$74

2025-12-11

Reason

UBS

Michael Brown

Price Target

$74

2025-12-11

initiated

Reason

UBS analyst Michael Brown assumed coverage of Carlyle with a Buy rating and $74 price target, noting strong sector fundamentals across 20 U.S. asset managers and brokers despite more mixed views on valuations and consensus expectations.The outlook favors undervalued growth, disciplined capital allocation, and firms positioned for margin expansion, while secular tailwinds support wealth brokers and independent investment banks whose robust earnings growth appears partly priced in, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Carlyle Group Inc (CG.O) is 13.28, compared to its 5-year average forward P/E of 10.98. For a more detailed relative valuation and DCF analysis to assess Carlyle Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

10.98

Current PE

13.28

Overvalued PE

13.24

Undervalued PE

8.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.74

Current PS

4.71

Overvalued PS

4.55

Undervalued PS

2.92

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 5714.58% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress areSelling! The selling amount has increased130.77%over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 5714.58% over the last month.

Sold

Bought

CG News & Events

Events Timeline

No data

News

8.5

01-08Yahoo Finance

Semafor Raises $30M in Funding, Valued at $330M After First Profitable Year

7.5

01-07Fool

Chevron Partners with Quantum Energy to Bid for Lukoil's $22 Billion Assets

8.5

01-06Newsfilter

Resonetics Acquires Med-Ally's IPG/EPG Assets to Enhance Medical Power Business

People Also Watch

Frequently Asked Questions

What is Carlyle Group Inc (CG) stock price today?

The current price of CG is 64.49 USD — it has decreased -0.29 % in the last trading day.

What is Carlyle Group Inc (CG)'s business?

The Carlyle Group Inc. is a global investment company. The Company's segments include Global Private Equity, Global Credit and Carlyle AlpInvest. The Global Private Equity segment advises the Company's buyout, growth, real estate, infrastructure, and natural resources funds. The segment also includes the NGP Carry Funds advised by NGP Energy Capital Management (NGP). The Global Credit segment advises funds and vehicles that pursue investment strategies including insurance solutions, liquid credit, opportunistic credit, direct lending, asset-backed finance, aviation finance, infrastructure credit, cross-platform credit products, and global capital markets. The Carlyle AlpInvest segment advises global private equity programs that pursue secondary purchases and financing of existing portfolios, managed co-investment programs, and primary fund investments. The Carlyle AlpInvest segment helps investors meet their objectives through tailored portfolio construction and investment selection.

What is the price predicton of CG Stock?

What is Carlyle Group Inc (CG)'s revenue for the last quarter?

Carlyle Group Inc revenue for the last quarter amounts to 780.50M USD, decreased -47.50 % YoY.

What is Carlyle Group Inc (CG)'s earnings per share (EPS) for the last quarter?

Carlyle Group Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Carlyle Group Inc (CG)'s fundamentals?

How many employees does Carlyle Group Inc (CG). have?

Carlyle Group Inc (CG) has 2300 emplpoyees as of January 09 2026.

What is Carlyle Group Inc (CG) market cap?

Today CG has the market capitalization of 23.31B USD.